Immunotherapy for mesothelioma

Riyaz Shah, FRCP, PhD, Maidstone and Tunbridge Wells NHS Trust, Kent, UK, talks on the latest updates in the management and treatment of mesothelioma, highlighting the introduction of immunotherapies including immune checkpoint inhibitors such as nivolumab in the second line, and comparing results versus single-agent chemotherapy. Dr Shah also comments on data from the CheckMate 743 study (NCT02899299) of nivolumab and ipilimumab versus chemotherapy in the first line for patients with unresectable pleural mesothelioma. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.